Beacon Hospice, An Amyedisys Company 815 Worcester Street, Springfield, MA, 01151 | |
(413) 205-1229 |
News Archive
Immediate breast reconstruction following mastectomy is becoming more prevalent. However, in breast cancer patients undergoing simultaneous chemotherapy, thrombotic complications can arise that can delay or significantly modify reconstructive plans. Outcomes of cases illustrating potential complications are published in the current issue of Annals of Medicine and Surgery.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.
Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.
Targeted postmortem testing to identify genetic mutations associated with sudden unexplained death (SUD) is an effective and less expensive way to determine risk to relatives than comprehensive cardiac testing of first degree relatives, according to research presented at the American Heart Association's Scientific Sessions 2009.
› Verified 9 days ago
Name | Beacon Hospice, An Amyedisys Company |
---|---|
Location | 815 Worcester Street, Springfield, Massachusetts |
Hospice ID | 221573 |
Category | Freestanding Hospice |
Ownership Type | Proprietary - Other |
Profit Type | FOR PROFIT |
SSA county code | 070 |
News Archive
Immediate breast reconstruction following mastectomy is becoming more prevalent. However, in breast cancer patients undergoing simultaneous chemotherapy, thrombotic complications can arise that can delay or significantly modify reconstructive plans. Outcomes of cases illustrating potential complications are published in the current issue of Annals of Medicine and Surgery.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.
Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.
Targeted postmortem testing to identify genetic mutations associated with sudden unexplained death (SUD) is an effective and less expensive way to determine risk to relatives than comprehensive cardiac testing of first degree relatives, according to research presented at the American Heart Association's Scientific Sessions 2009.
› Verified 9 days ago
NPI Number | 1508012204 |
Organization Name | Beacon Hospice, Llc |
Address | 815 Worcester St Springfield, Massachusetts, 01151 |
Phone Number | (413)543-3133 |
News Archive
Immediate breast reconstruction following mastectomy is becoming more prevalent. However, in breast cancer patients undergoing simultaneous chemotherapy, thrombotic complications can arise that can delay or significantly modify reconstructive plans. Outcomes of cases illustrating potential complications are published in the current issue of Annals of Medicine and Surgery.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.
Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.
Targeted postmortem testing to identify genetic mutations associated with sudden unexplained death (SUD) is an effective and less expensive way to determine risk to relatives than comprehensive cardiac testing of first degree relatives, according to research presented at the American Heart Association's Scientific Sessions 2009.
› Verified 9 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 97.5 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 95.9 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 97.4 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 97.1 | 97.3 |
Patients who got timely treatment for shortness of breath | 85.2 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 100.0 | 93.3 |
News Archive
Immediate breast reconstruction following mastectomy is becoming more prevalent. However, in breast cancer patients undergoing simultaneous chemotherapy, thrombotic complications can arise that can delay or significantly modify reconstructive plans. Outcomes of cases illustrating potential complications are published in the current issue of Annals of Medicine and Surgery.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.
Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.
Targeted postmortem testing to identify genetic mutations associated with sudden unexplained death (SUD) is an effective and less expensive way to determine risk to relatives than comprehensive cardiac testing of first degree relatives, according to research presented at the American Heart Association's Scientific Sessions 2009.
› Verified 9 days ago
Home Health Aides | 4.9 |
Counselors | 1 |
Homemakers | 0.1 |
Medical Social Workers | 1 |
Physicians | 1 |
Registered Nurses | 6 |
Other Personnel | 6 |
Total Employees | 20 |
---|
News Archive
Immediate breast reconstruction following mastectomy is becoming more prevalent. However, in breast cancer patients undergoing simultaneous chemotherapy, thrombotic complications can arise that can delay or significantly modify reconstructive plans. Outcomes of cases illustrating potential complications are published in the current issue of Annals of Medicine and Surgery.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.
Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.
Targeted postmortem testing to identify genetic mutations associated with sudden unexplained death (SUD) is an effective and less expensive way to determine risk to relatives than comprehensive cardiac testing of first degree relatives, according to research presented at the American Heart Association's Scientific Sessions 2009.
› Verified 9 days ago
Others | 0.3 |
Total Volunteers | 0.3 |
---|
News Archive
Immediate breast reconstruction following mastectomy is becoming more prevalent. However, in breast cancer patients undergoing simultaneous chemotherapy, thrombotic complications can arise that can delay or significantly modify reconstructive plans. Outcomes of cases illustrating potential complications are published in the current issue of Annals of Medicine and Surgery.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
The American Pain Society, www.americanpainsociety.org, today condemned the Trump Administration's proposed 19 percent cut in funding for the National Institutes of Health and warned that such a draconian budget reduction would devastate biomedical research in the United States unless Congress acted to prevent it.
Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.
Targeted postmortem testing to identify genetic mutations associated with sudden unexplained death (SUD) is an effective and less expensive way to determine risk to relatives than comprehensive cardiac testing of first degree relatives, according to research presented at the American Heart Association's Scientific Sessions 2009.
› Verified 9 days ago
Baystate Vna And Hospice Location: 50 Maple Street, P O Box 9058, Springfield, Massachusetts, 01102 Phone: (413) 205-1229 |
Beacon Hospice, An Amyedisys Company Location: 815 Worcester Street, Springfield, Massachusetts, 01151 Phone: (413) 205-1229 |